RESUMEN
Basic fibroblast growth factor (bFGF) can exert mitogenic and viability-promoting effects in a wide range of biological systems. The biochemical activities mediating the cell survival function of bFGF are largely unknown. We report here that exposure of fibroblasts to bFGF, which confers upon them increased survival, also causes at the same time an increase in cellular levels of the Mdm2 oncoprotein. Cells constitutively exposed to a bFGF autocrine loop are more refractory to killing by cisplatin. This increased chemoresistance coincides with elevated Mdm2 and reduced activation of the endogenous p53, resulting in inefficient transcriptional activation of the bax gene promoter. Importantly, unlike Mdm2 accumulation in fibroblasts exposed to DNA damage, induction of Mdm2 by bFGF does not occur through a p53-mediated pathway. The role of p53 in DNA damage-induced apoptosis and the ability of Mdm2 to block p53-mediated cell death are well established. These findings therefore suggest that induction of Mdm2 and the subsequent inhibition of p53 function may contribute, at least partially, to the anti-apoptotic effects of bFGF and possibly some other survival factors.
Asunto(s)
Factor 2 de Crecimiento de Fibroblastos/farmacología , Proteínas Nucleares , Proteínas Proto-Oncogénicas c-bcl-2 , Proteínas Proto-Oncogénicas/metabolismo , Células 3T3/efectos de los fármacos , Animales , Antineoplásicos , Apoptosis/efectos de los fármacos , Apoptosis/genética , Supervivencia Celular/efectos de los fármacos , Supervivencia Celular/genética , Cisplatino/farmacología , Medios de Cultivo , Inhibidor p21 de las Quinasas Dependientes de la Ciclina , Ciclinas/efectos de los fármacos , Ciclinas/genética , Daño del ADN/efectos de los fármacos , Factor 2 de Crecimiento de Fibroblastos/metabolismo , Regulación Neoplásica de la Expresión Génica , Ratones , Regiones Promotoras Genéticas , Proteínas Proto-Oncogénicas/efectos de los fármacos , Proteínas Proto-Oncogénicas/genética , Proteínas Proto-Oncogénicas c-mdm2 , Ratas , Proteína p53 Supresora de Tumor/genética , Proteína p53 Supresora de Tumor/metabolismo , Proteína X Asociada a bcl-2RESUMEN
Normal fibroblasts are dependent on adhesion to a substrate for cell cycle progression. Adhesion-deprived Rat1 cells arrest in the G1 phase of the cell cycle, with low cyclin E-dependent kinase activity, low levels of cyclin D1 protein, and high levels of the cyclin-dependent kinase inhibitor p27kip1. To understand the signal transduction pathway underlying adhesion-dependent growth, it is important to know whether prevention of any one of these down-regulation events under conditions of adhesion deprivation is sufficient to prevent the G1 arrest. To that end, sublines of Rat1 fibroblasts capable of expressing cyclin E, cyclin D1, or both in an inducible manner were used. Ectopic expression of cyclin D1 was sufficient to allow cells to enter S phase in an adhesion-independent manner. In contrast, cells expressing exogenous cyclin E at a level high enough to overcome the p27kip1-imposed inhibition of cyclin E-dependent kinase activity still arrested in G1 when deprived of adhesion. Moreover, expression of both cyclins D1 and E in the same cells did not confer any additional growth advantage upon adhesion deprivation compared to the expression of cyclin D1 alone. Exogenously expressed cyclin D1 was down-regulated under conditions of adhesion deprivation, despite the fact that it was expressed from a heterologous promoter. The ability of cyclin D1-induced cells to enter S phase in an adhesion-independent manner disappears as soon as cyclin D1 proteins disappear. These results suggest that adhesion-dependent cell cycle progression is mediated through cyclin D1, at least in Rat1 fibroblasts.
Asunto(s)
Biomarcadores de Tumor , Adhesión Celular , Proteínas de Ciclo Celular , Ciclo Celular , Ciclinas/metabolismo , Proteínas Oncogénicas/metabolismo , Proteínas Supresoras de Tumor , Animales , Células Cultivadas , Ciclina D1 , Inhibidor p27 de las Quinasas Dependientes de la Ciclina , Quinasas Ciclina-Dependientes/antagonistas & inhibidores , Regulación hacia Abajo , Inhibidores Enzimáticos/metabolismo , Fibroblastos/citología , Genes Supresores de Tumor , Proteínas Asociadas a Microtúbulos/metabolismo , RatasRESUMEN
Mutations in the tumor suppressor p53 are a common event in hepatocellular carcinoma (HCC). Because HCCs typically occur in livers with chronic injury and impaired function, we have explored the role of wild-type p53 in regulating the growth and differentiation of Hep 3B hepatoma cells, a p53-negative line derived from a liver cancer. Stable Hep 3B cell lines were generated in which inducible p53 was introduced using either a temperature-sensitive mutant (p53val135) or a tamoxifen-regulated p53-estrogen receptor chimera (p53-mERtm-pBabepuro). In both cell lines, induction of transcriptionally active p53 was confirmed by assessing several p53 targets: Mdm2 protein, p21waf1 mRNA and protein, and the cyclin G promoter. Despite marked induction of p21waf1, cells with active p53 failed to undergo growth arrest, which is probably due to the presence of a non-functional retinoblastoma protein (pRb) in these cells. Apoptosis also was not observed, even after prolonged (48 h) serum starvation or exposure to cisplatinum. Lack of apoptosis was correlated with unchanged bax mRNA levels following p53 induction. Additionally, albumin mRNA levels remained unchanged, and there was no change in basal transactivation of a reporter containing the promoter of the haptoglobin gene, encoding an acute phase protein. This suggests that growth arrest may be required to promote liver-specific gene expression. Overall, our data demonstrate that introduction of transcriptionally active p53 does not alter the malignant, dedifferentiated phenotype of Hep 3B hepatoma cells. Hence, not all cancer cells are equally responsive to the re-activation of wild-type 53. The ability of a cancer cell to undergo p53-mediated phenotypic alterations may depend on the retention of functional downstream effector pathways.
Asunto(s)
Apoptosis , Carcinoma Hepatocelular/patología , Genes p53 , Neoplasias Hepáticas/patología , Diferenciación Celular , División Celular , Daño del ADN , Regulación Neoplásica de la Expresión Génica , Humanos , Proteína de Retinoblastoma/metabolismo , Albúmina Sérica/metabolismo , Tamoxifeno/farmacología , Transfección , Células Tumorales CultivadasRESUMEN
In cells of higher eukaryotes, cyclin D-dependent kinases Cdk4 and Cdk6 and, possibly, cyclin E-dependent Cdk2 positively regulate the G1- to S-phase transition, by phosphorylating the retinoblastoma protein (pRb), thereby releasing E2F transcription factors that control S-phase genes. Here we performed microinjection and transfection experiments using rat R12 fibroblasts, their derivatives conditionally overexpressing cyclins D1 or E, and human U-2-OS cells, to explore the action of G1 cyclins and the relationship of E2F and cyclin E in S-phase induction. We demonstrate that ectopic expression of cyclin E, but not cyclin D1, can override G1 arrest imposed by either the p16INK4a Cdk inhibitor specific for Cdk4 and Cdk6 or a novel phosphorylation-deficient mutant pRb. Several complementary approaches to assess E2F activation, including quantitative reporter assays in live cells, showed that the cyclin E-induced S phase and completion of the cell division cycle can occur in the absence of E2F-mediated transactivation. Together with the ability of cyclin E to overcome a G1 block induced by expression of dominant-negative mutant DP-1, a heterodimeric partner of E2Fs, these results provide evidence for a cyclin E-controlled S phase-promoting event in somatic cells downstream of or parallel to phosphorylation of pRb and independent of E2F activation. They furthermore indicate that a lack of E2F-mediated transactivation can be compensated by hyperactivation of this cyclin E-controlled event.
Asunto(s)
Proteínas Portadoras , Proteínas de Ciclo Celular , Ciclinas/metabolismo , Proteínas de Unión al ADN , Interfase/fisiología , Proteína de Retinoblastoma/metabolismo , Factores de Transcripción/metabolismo , Animales , Células Cultivadas , Ciclina D1 , Ciclinas/genética , Factores de Transcripción E2F , Fibroblastos/citología , Fase G1/fisiología , Genes Reporteros , Humanos , Luciferasas/genética , Luciferasas/aislamiento & purificación , Ratones , Microinyecciones , Mutación , Proteínas Oncogénicas/genética , Proteínas Oncogénicas/metabolismo , Fosforilación , Ratas , Proteína 1 de Unión a Retinoblastoma , Fase S/fisiología , Factor de Transcripción DP1 , TransfecciónRESUMEN
Deregulation of the pRb/E2F pathway leads to disruption of the normal control of the G1/S transition, and is associated with transformation. However, recent accumulated evidence suggest that under certain circumstances deregulation of the pRb/E2F pathway can also lead to apoptotic cell death. Apoptosis was shown to be induced by expression of DNA tumor virus oncoproteins, knockout of the rb gene, and expression of E2F from heterologous promoter. Since phosphorylation of pRb by G1 cyclin-dependent kinases (Cdks) causes its inactivation, we examined whether deregulation of G1 Cdks, also drives apoptosis. We have used rat fibroblast cell lines capable of expressing cyclin E, cyclin D1, or both, in an inducible manner, through a tetracycline responsive promoter. We show here that ectopic expression of cyclins D1 and E in rat fibroblasts under serum starvation, leads to deregulated entry into S phase, and subsequently to apoptotic cell death. Furthermore, expression of cyclin D1 alone is sufficient to provoke apoptosis, whereas expression of cyclin E alone during serum starvation does not. Moreover, expression of either cyclins D1 and E, and cyclin D1 alone, under serum starvation led to a significant increase in the fraction of hyper-phosphorylated pRb whereas cyclin E expression alone did not. These results demonstrate that expression of cyclin D1 from heterologous promoter leads to apoptosis in serum starved cells, which may be mediated by phosphorylation of pRb.
Asunto(s)
Apoptosis/fisiología , Ciclinas/metabolismo , Fase G1/fisiología , Proteínas Oncogénicas/metabolismo , Proteína de Retinoblastoma/metabolismo , Fase S/fisiología , Animales , Ciclina D1 , ADN/metabolismo , Fosforilación , RatasRESUMEN
Alpha interferon is a potent growth inhibitor of Daudi Burkitt's lymphoma cells. We show here that alpha-interferon signaling interacted simultaneously with several components of the basic cell cycle machinery, causing cells to enter into a state that had many features characteristic of the G0 state. Within a few hours after alpha-interferon treatment, cyclin D3 mRNA and protein levels dropped to undetectable levels and, in parallel, the activities of cyclin A- and cyclin E-associated kinases were significantly reduced. The latter resulted from the rapid alpha-interferon-mediated elimination of cdc25A, a phosphatase that is required for antagonism of negative tyrosine phosphorylation of cdk2 in cyclin-cdk complexes. This regulation represents a novel mechanism through which an external inhibitory cytokine interacts with the cell cycle machinery. At later time points after alpha-interferon treatment, the levels of the 55-kDa slowly migrating hyperphosphorylated form of cyclin E and of cyclin A were also reduced. The antiproliferative effects were reversible, and cultures from which alpha interferon was removed reentered S phase after a lag that typically corresponded to approximately two doubling times. During this lag period, the expression of cyclin D3 and cyclin A, as well as of the cdc25A phosphatase, continued to be switched off, in spite of the removal of alpha interferon from the cell surface. In contrast, c-myc, which represents another downstream target gene that is subjected to negative regulation by alpha interferon, was relieved from suppression much earlier, concomitant with the decay in early signaling of the cytokine. The delayed pattern of cyclin reexpression provides evidence that alpha-interferon signaling imposes a G0-like state on this system.
Asunto(s)
Proteínas de Ciclo Celular/biosíntesis , Ciclo Celular/efectos de los fármacos , Ciclinas/biosíntesis , Regulación Neoplásica de la Expresión Génica/efectos de los fármacos , Interferón-alfa/farmacología , Fosfoproteínas Fosfatasas/biosíntesis , Linfoma de Burkitt , Proteínas de Ciclo Celular/metabolismo , División Celular/efectos de los fármacos , Línea Celular , Ciclina D3 , Quinasas Ciclina-Dependientes/metabolismo , Ciclinas/aislamiento & purificación , Proteínas de Unión al GTP/biosíntesis , Humanos , Cinética , Fosfoproteínas Fosfatasas/metabolismo , Fase de Descanso del Ciclo Celular , Supresión Genética , Acetato de Tetradecanoilforbol/farmacología , Factores de Tiempo , Células Tumorales Cultivadas , Fosfatasas cdc25RESUMEN
We have created fibroblast cell lines that express cyclin A under the control of a tetracycline-repressible promoter. When stimulated to reenter the cell cycle after serum withdrawal, these cells were advanced prematurely into S phase by induction of cyclin A. In an asynchronous population, induction of cyclin A caused a decrease in the percentage of cells in G1. These results demonstrate that expression of cyclin A is rate limiting for the G1-to-S transition and suggest that cyclin A can function as a G1 cyclin. Although the level of exogenous cyclin A was constant throughout the cell cycle, its associated kinase activity increased as cells approached S phase. Low kinase activity in early G1 was found to correlate with the presence of p27Kip1 in cyclin A-associated complexes, while high kinase activity in late G1 was correlated with its absence. These results suggest that a function of p27Kip1 in G1 is to prevent premature activation of cyclin A-associated kinase. Cyclin A expression in early G1 led to phosphorylation of the product of the retinoblastoma susceptibility gene (pRb). Thus, cyclin A expression can be rate limiting for pRb phosphorylation, implicating pRb as a physiological substrate of the cyclin A-dependent kinase. Taken together, these results demonstrate that deregulated expression of cyclin A can perturb the normal regulation of the G1-to-S transition.
Asunto(s)
Proteínas de Ciclo Celular , Ciclinas/metabolismo , Fase G1/fisiología , Proteínas Asociadas a Microtúbulos/metabolismo , Proteínas Quinasas/metabolismo , Fase S/fisiología , Proteínas Supresoras de Tumor , Animales , Línea Celular , Inhibidor p27 de las Quinasas Dependientes de la Ciclina , Humanos , Fosforilación , Ratas , Proteína de Retinoblastoma/metabolismoRESUMEN
Ectopic expression of cyclins D1 and E was previously shown to accelerate the G1/S-phase transition, indicating that both classes of G1 cyclin control an event(s) that is rate limiting for entry into S phase. In order to determine whether cyclins D1 and E control the same or two different rate-limiting events, we have created cell lines that express both cyclins in an inducible manner. We show here that ectopic expression of both cyclins E and D1 in the same cell has an additive effect on shortening of the G1 interval relative to expression of any single cyclin. In order to further explore the molecular basis for G1 cyclin action, we used cell lines capable of expressing cyclin D1, E, or both prematurely and measured the effect of cyclin expression in early G1 on phosphorylation of the retinoblastoma susceptibility gene product (pRb). We show here that while premature expression of either cyclin alone advances the G1/S-phase transition to the same extent, premature expression of cyclin D1 leads to immediate appearance of hyperphosphorylated pRb, while premature expression of cyclin E does not. Ectopic expression of both cyclins E and D1 in the same cell has an additive effect on shortening of the G1 interval, while the effect on pRb phosphorylation is similar to the effect of cyclin D1 alone. These results suggest that cyclins E and D1 control two different events, both rate limiting for the G1/S-phase transition, and that pRb phosphorylation might be the rate-limiting event controlled by cyclin D1.
Asunto(s)
Ciclinas/metabolismo , Fase G1/fisiología , Proteínas Oncogénicas/metabolismo , Proteína de Retinoblastoma/metabolismo , Fase S/fisiología , Animales , Células Clonales , Ciclina D1 , Ciclinas/genética , Fibroblastos/citología , Regulación de la Expresión Génica , Immunoblotting , Modelos Biológicos , Proteínas Oncogénicas/genética , Fosforilación , Pruebas de Precipitina , Ratas , Proteínas Recombinantes/metabolismo , Factores de TiempoRESUMEN
Conditional overexpression of human cyclins B1, D1, and E was accomplished by using a synthetic cDNA expression system based on the Escherichia coli tetracycline repressor. After induction of these cyclins in asynchronous Rat-1 fibroblasts, a decrease in the length of the G1 interval was observed for cyclins D1 and E, consistent with an acceleration of the G1/S phase transition. We observed, in addition, a compensatory lengthening of S phase and G2 so that the mean cell cycle length in populations constitutively expressing these cyclins was unchanged relative to those of their uninduced counterparts. We found that expression of cyclin B1 had no effect on cell cycle dynamics, despite elevated levels of cyclin B-associated histone H1 kinase activity. Induction of cyclins D1 and E also accelerated entry into S phase for synchronized cultures emerging from quiescence. However, whereas cyclin E exerted a greater effect than cyclin D1 in asynchronous cycling cells, cyclin D1 conferred a greater effect upon stimulation from quiescence, suggesting a specific role for cyclin D1 in the G0-to-G1 transition. Overexpression of cyclins did not prevent cells from entering into quiescence upon serum starvation, although a slight delay in attainment of quiescence was observed for cells expressing either cyclin D1 or cyclin E. These results suggest that cyclins D1 and E are rate-limiting activators of the G1-to-S phase transition and that cyclin D1 might play a specialized role in facilitating emergence from quiescence.
Asunto(s)
Ciclo Celular , Ciclinas/fisiología , Proteínas Oncogénicas/fisiología , Animales , Línea Celular , Medios de Cultivo , Ciclina D1 , Técnicas In Vitro , TransfecciónRESUMEN
Cyclin-dependent kinases (Cdks) control the major cell cycle transitions in eukaryotic cells. On the basis of a variety of experiments where cyclin function either is impaired or enhanced, D-type cyclins as well as cyclins E and A have been linked to G1 and G1/S phase roles in mammalian cells. We therefore sought to determine if agents that block the G1/S phase transition do so at the level of regulating the Cdk activities associated with these cyclins. A variety of conditions that lead to G1 arrest were found to correlate with accumulation of G1-specific Cdk inhibitors, including treatment of fibroblasts with ionizing radiation, treatment of epithelial cells with TGF-beta, treatment of HeLa cells with the drug lovastatin, and removal of essential growth factors from a variety of different cell types. Mechanistically, inhibition of Cdks was found to involve the stoichiometric binding of Cdk inhibitor proteins. p21Waf1/Cip1 was associated with DNA damage induced arrest while p27Kip1/p28Ick1 accumulated under a variety of antiproliferative conditions.
Asunto(s)
Quinasas Ciclina-Dependientes/fisiología , Ciclinas/fisiología , Fase G1 , Animales , Ciclo Celular/fisiología , Quinasas Ciclina-Dependientes/antagonistas & inhibidores , HumanosRESUMEN
The effects that three different growth inhibitory cytokines exert on expression and function of members of the Jun family were studied in this work. M1 myeloblastic cells were chosen for this purpose because of their high growth sensitivity to interleukin 6 (IL-6), transforming growth factor beta 1 and alpha- and beta-interferons. It is reported here that IL-6 elevated the junB and c-jun mRNA levels and induced the formation of a novel DNA-protein complex with high sequence specificity to 12-O-tetradecanoylphorbol-13-acetate response element (TRE) oligonucleotides. This IL-6 induced TRE binding complex was abolished by anti-Jun specific antibodies and was efficiently competed by an oligonucleotide that comprises the mouse homologue of a previously described human c-myc negative DNA element. It persisted in cells for at least 48 h after IL-6 treatment and failed to be induced by alpha- and beta-interferons or by transforming growth factor beta 1, which affected differently the pattern of jun mRNA expression. To further explore regulatory and functional aspects of this induced TRE binding activity, an IL-6 resistant M1 clone was isolated and further analyzed. This clone carried a postreceptor deficiency that abrogated completely the growth inhibitory responses to IL-6 but did not interfere with the induction of two differentiation related cell surface markers. Interestingly, the IL-6 resistant clone had lost two molecular responses to IL-6, induction of TRE binding activity and suppression of the c-myc gene. The data correlate the IL-6 induced AP1 activity with the suppression of c-myc and growth inhibition.
Asunto(s)
Proteínas de Unión al ADN/metabolismo , Interleucina-6/farmacología , Leucemia Mieloide Aguda/metabolismo , Factores de Transcripción/metabolismo , Animales , Secuencia de Bases , Diferenciación Celular/efectos de los fármacos , División Celular/efectos de los fármacos , Células Clonales/efectos de los fármacos , Genes jun , Interferón Tipo I/farmacología , Ratones , Datos de Secuencia Molecular , ARN Mensajero/biosíntesis , Acetato de Tetradecanoilforbol/farmacología , Factor de Crecimiento Transformador beta/farmacología , Células Tumorales CultivadasRESUMEN
Murine radiation-induced acute myeloid leukemia (RI-AML) may be considered as the experimental counterpart of human secondary leukemia. Three new myelomonocytic cell lines derived from RI-AML and carrying a partially deleted chromosome 2 are described. The RI-AML cells responded with increased proliferation after being incubated with the hemopoietic growth factors rG-CSF, rGM-CSF and IL-3. Increased proliferation of the same extent without any effect in differentiation, was also demonstrated in the RI-AML cells after incubation with IL-6 and with mouse lung conditioned medium (CM) and Krebs ascites tumor cells CM which induce differentiation in normal and most leukemic myeloid cells. Down-regulation of the c-myc gene and induction of (2'-5') oligo-adenylate synthetase (reflecting autocrine interferon secretion), two essential mechanisms operating during arrest of growth and concomitant differentiation, were demonstrated to be absent in RI-AML cells. In contrast, the M1 cells responded to the above differentiating factors with growth arrest and differentiation and with appropriate c-myc down-regulation and synthetase induction. The genetic basis for the distinct RI-AML cells' behavior may be connected with the loss or structural and/or functional abnormalities of DNA sequences located in the deleted part of chromosome 2 or in the respective allele. The presently described new RI-AML cell lines may be used for studies concerning myeloid leukemogenesis in general and secondary leukemia in particular.
Asunto(s)
Deleción Cromosómica , Leucemia Mieloide/genética , Leucemia Mieloide/patología , Leucemia Inducida por Radiación/genética , Leucemia Inducida por Radiación/patología , Proteínas Proto-Oncogénicas c-myc/análisis , ARN Neoplásico/análisis , 2',5'-Oligoadenilato Sintetasa/análisis , Animales , División Celular/efectos de los fármacos , Cariotipificación , Leucemia Mieloide/enzimología , Leucemia Inducida por Radiación/enzimología , Ratones , Células Tumorales CultivadasRESUMEN
One approach to identify postreceptor molecular events that transduce the negative-growth signals of inhibitory cytokines is to analyze the cytokine-induced modifications in the expression of cell-cycle-controlling genes. Here we report that suppression of phosphorylation of the retinoblastoma gene product (pRb) is a receptor-generated event triggered by interferons and interleukin 6 (IL-6) in hematopoietic cell lines. The conversion of pRb to the underphosphorylated forms occurs concomitantly with the decline in c-myc protein expression and both events precede the G0/G1-phase arrest induced by the cytokines. Loss of IL-6-induced c-myc responses in cells that have been stably transfected with constitutive versions of the c-myc gene abrogates the typical G0/G1-phase arrest but does not prevent the specific dephosphorylation of pRb. Conversely, depletion of protein kinase C from cells interferes with part of the interferon-induced suppression of pRb phosphorylation and relieves the G0/G1-phase cell-cycle block without affecting the extent of c-myc inhibition. None of the cytokines, including transforming growth factor beta, reduce the phosphorylation of pRb in S-phase-blocked cells. In contrast, the other IL-6-induced molecular responses, including the decline in c-myc mRNA levels, are not phase-specific and develop normally in S-phase-blocked cells that are depleted of the underphosphorylated functional forms of pRb. These and the suppression of pRb phosphorylation, which occur independently of each other, and suggest that the development of the interferon- or IL-6-induced G0/G1-specific arrest requires at least these two receptor-generated events.
Asunto(s)
Ciclo Celular , Células Madre Hematopoyéticas/metabolismo , Interferones/farmacología , Interleucina-6/farmacología , Proteína de Retinoblastoma/metabolismo , Animales , Ciclo Celular/efectos de los fármacos , Línea Celular , Ciclinas/metabolismo , Expresión Génica , Humanos , Técnicas In Vitro , Ratones , Fosfoproteínas/metabolismo , Fosforilación , Proteína Quinasa C/fisiología , Proteínas Proto-Oncogénicas c-myc/genética , Proteínas Proto-Oncogénicas c-myc/metabolismo , ARN Mensajero/genética , Acetato de Tetradecanoilforbol/farmacología , Factor de Crecimiento Transformador beta/farmacología , Células Tumorales CultivadasRESUMEN
Wild-type p53 protein has many properties consistent with its being the product of a tumour suppressor gene. Although the normal roles of tumour suppressor genes are still largely unknown, it seems that they could be involved in promoting cell differentiation as well as in mediating growth arrest by growth-inhibitory cytokines. Hence, the abrogation of wild-type p53 expression, which is a common feature of many tumours, could eliminate these activities. We have now tested this notion by restoring the expression of p53 in a murine myeloid leukaemic cell line that normally lacks p53. The use of a temperature-sensitive p53 mutant allowed us to analyse cells in which the introduced p53 had either wild-type or mutant properties. Although there seemed to be no effect on differentiation, the introduction of wild-type p53 resulted in rapid loss of cell viability in a way characteristic of apoptosis (programmed cell death). The effect of wild-type p53 was counteracted by interleukin-6. Thus products of tumour suppressor genes could be involved in restricting precursor cell populations by mediating apoptosis.
Asunto(s)
Supervivencia Celular , Interleucina-6/farmacología , Leucemia Mieloide/genética , Proteína p53 Supresora de Tumor/farmacología , Animales , Diferenciación Celular , Genes p53 , Ratones , Mutación , Transfección , Células Tumorales CultivadasRESUMEN
The proliferation of M1 myeloblastic cells can be specifically restricted at the G0/G1 phase of the cell cycle by exposure to alpha- and beta-interferons or to interleukin 6. The latter cytokine also induces the morphological and functional differentiation of these myeloblasts toward monocytes. Each of these two different cytokines suppresses the expression of the c-myc nuclear oncogene, and the selective reduction in c-myc mRNA and protein precedes the cell cycle changes. In order to investigate whether one or more of the growth-suppressive effects of interferon and interleukin 6 are mediated by c-myc reduction, M1 cells were transfected with SV40-driven c-myc plasmid, whose expression fails to be turned off by these two cytokines. A detailed analysis of the responses to interferon and to interleukin 6 revealed that all of the myc-transfected clones have lost the cytokine-mediated G0/G1 type of growth arrest. However, not all of the growth responses to these cytokines were rescued by this specific genetic manipulation, and the cytokine-treated transfected cells stopped to proliferate in a new fashion which was not cell cycle specific. In addition, the myc-transfected cells developed the differentiated phenotype in response to interleukin 6, as determined by the morphological change, expression of Fc receptors, and cytochemical analysis, suggesting that these molecular events can occur in the monocyte cell lineage in spite of the abnormal constitutive expression of c-myc.(ABSTRACT TRUNCATED AT 250 WORDS)
Asunto(s)
Fase G1/efectos de los fármacos , Regulación Neoplásica de la Expresión Génica/fisiología , Genes myc/fisiología , Interferones/farmacología , Interleucina-6/farmacología , Leucemia Mieloide Aguda/genética , Fase de Descanso del Ciclo Celular/efectos de los fármacos , Animales , Diferenciación Celular/efectos de los fármacos , Regulación hacia Abajo/efectos de los fármacos , Ratones , Virus 40 de los Simios/genética , Transfección/genética , Células Tumorales CultivadasRESUMEN
In a previous study we demonstrated that many hematopoietic tumor cells are resistant to the inhibitory effects that interferon exerts on c-myc mRNA expression without losing other receptor-mediated intracellular responses (M. Einat, D. Resnitzky, and A. Kimchi, Nature [London] 313:597-600). We report here that this partial resistance was overridden in two independent stable somatic cell hybrids prepared by fusion between sensitive and resistant cells. The c-myc mRNA transcribed from the active allele of the resistant parent cell was reduced by interferon within the context of the cell hybrid. It was therefore concluded that changes in the cis-acting sequences of c-myc were not involved in this type of relaxed regulation and that resistance resulted rather from inactivation or loss of postreceptor elements which operate in trans. The growth-stimulating effect that this genetic deregulation might have on cells was tested in experimental systems of cell differentiation in which an autocrine interferon is produced. For that purpose we isolated variant clones of M1 myeloid cells which were partially resistant to alpha and beta interferons and tested their growth behavior during in vitro-induced differentiation. The resistant clones displayed higher proliferative activity on days 2 and 3 of differentiation than did the sensitive clones, which stopped proliferating. The loss of c-myc responses to the self-produced interferon disrupted the normal cessation of growth during differentiation and therefore might lead cells along the pathway of neoplasia.
Asunto(s)
Regulación de la Expresión Génica/efectos de los fármacos , Interferón Tipo I/farmacología , Proteínas Proto-Oncogénicas/genética , Proto-Oncogenes , Linfoma de Burkitt/metabolismo , División Celular , Genes Recesivos , Variación Genética , Humanos , Células Híbridas/metabolismo , Proteínas Proto-Oncogénicas c-myc , ARN Mensajero/biosíntesis , Supresión GenéticaRESUMEN
The protein p53 is functionally implicated in the normal regulation of cell proliferation. We have previously reported that the rate of p53 protein synthesis is reduced during the cessation of cellular proliferation which accompanies the in vitro induced differentiation of Friend-erythroleukemia cells. In this work we followed the p53 mRNA expression during the differentiation of these cells. We report on a new type of p53 mRNA with a slower electrophoretic mobility on gels, which appeared in the cytoplasmic fraction of the erythroleukemia cells between 1 to 3 days following induction of differentiation and persisted in the cells until Day 7. The larger type of p53 mRNA was found associated with polysomes, suggesting that it is translatable in cells. The difference in size between the noninduced and the differentiation-specific type of p53 mRNAs (about 200 nucleotides) was not abrogated following the deadenylation of the mRNAs, thus excluding the possibility that the altered size might result from a longer poly(A) tract. S1 nuclease mapping of the 3' termini of the p53 mRNAs revealed that the 3' ends of both p53 mRNA types were identical, suggesting that either alternative splicing or a longer 5' noncoding region could cause this heterogeneity in p53 mRNA transcripts.
Asunto(s)
Diferenciación Celular , División Celular , Leucemia Eritroblástica Aguda/patología , Proteínas de Neoplasias/genética , Fosfoproteínas/genética , Animales , Línea Celular , Citoplasma/metabolismo , Dimetilsulfóxido/farmacología , Regulación de la Expresión Génica , Ratones , Peso Molecular , ARN Mensajero/metabolismo , Proteína p53 Supresora de TumorRESUMEN
Different hematopoietic cells produce minute amounts of beta-related interferon (IFN) following induction of differentiation by chemical or natural inducers. The endogenous IFN binds to type I cell surface receptors and modulates gene expression in the producer cells. We show that self-induction of two members of the IFN-induced gene family differs in the dose response sensitivity and the prolonged kinetics of mRNA accumulation from the response to exogenous IFN-beta 1. Production and response to endogenous IFN are also detected when bone marrow precursor cells differentiate to macrophages after exposure to colony stimulating factor 1. In M1 myeloid cells induced to differentiate by lung-conditioned medium, addition of antibodies against IFN-beta partially abrogates the reduction of c-myc mRNA and the loss in cell proliferative activity, which both occur during differentiation. The endogenous IFN therefore functions as an autocrine growth inhibitor that participates in controlling c-myc suppression and the specific G0/G1 arrest during terminal differentiation of hematopoietic cells.
Asunto(s)
Inhibidores de Crecimiento , Hematopoyesis , Interferón Tipo I/fisiología , Proteínas Proto-Oncogénicas/genética , 2',5'-Oligoadenilato Sintetasa/biosíntesis , Animales , Células de la Médula Ósea , Ciclo Celular , Diferenciación Celular , Inducción Enzimática , Regulación de la Expresión Génica , Antígenos HLA/genética , Humanos , Técnicas Inmunológicas , Interferón Tipo I/inmunología , Macrófagos/citología , Ratones , Proto-Oncogenes , ARN Mensajero/genética , Receptores Inmunológicos/inmunología , Receptores Inmunológicos/fisiología , Receptores de InterferónRESUMEN
The G0/G1 to S transition in quiescent BALB/c 3T3 cells stimulated by serum growth factors can be specifically blocked by the administration of interferon (IFN) to the system. In the present communication, we studied whether IFN inhibits the early events in the G0/G1 phase that are initiated by the platelet-derived growth factor (PDGF). The results show that IFN inhibits most of the PDGF-mediated increase of c-myc, ornithine decarboxylase, and beta-actin mRNAs measured 3 hr after stimulation. c-fos mRNA levels are reduced by IFN as early as 20 min after exposure of the quiescent cells to PDGF. The expression of several genes that belong to the competence gene family is, therefore, inhibited by IFN and this could account for the failure of the IFN-treated cells to enter into the S phase when growth factors present in the platelet-poor plasma are added. We also report that the PDGF-mediated increase in the uptake of deoxyglucose is not impaired by IFN, thus suggesting that the early effects of IFN on gene expression do not result from inhibition of binding of PDGF to its cell-surface receptors. Unlike the direct stimulatory effect of PDGF, which is not sensitive to cycloheximide, the inhibitory effect of IFN on c-myc mRNA levels depends in part on protein synthesis. We propose that a putative product of one of the IFN-induced genes could mediate the decrease in expression of the PDGF-regulated gene family.
Asunto(s)
Regulación de la Expresión Génica/efectos de los fármacos , Interferones/farmacología , Factor de Crecimiento Derivado de Plaquetas/farmacología , Animales , Células Cultivadas , ADN/biosíntesis , Ratones , Ratones Endogámicos BALB C , Oncogenes , ARN Mensajero/biosíntesisRESUMEN
It has recently been reported that c-myc is an inducible gene, regulated directly by growth signals which promote proliferation and expressed in a cell-cycle dependent manner. Because various leukaemic cell lines express high levels of c-myc messenger RNA, it was of interest to discover whether the gene could be down-regulated in these cells by a growth inhibitor such as interferon (IFN). We show here that in Daudi Burkitt's lymphoma cells, IFN-alpha produces a five- to sevenfold reduction in c-myc mRNA through a decreased rate of c-myc gene transcription. By isolating a growth-resistant Daudi cell variant that had escaped from this down-regulation, we provide the first clear link between reduction of c-myc mRNA and the IFN-mediated G0/G1 arrest characteristic of Daudi cells. Furthermore, by screening other cell lines, we demonstrate the heterogeneity of human leukaemic cells with respect to these criteria. Thus, IFN-alpha fails to reduce the c-myc mRNA and to change the cell-cycle distribution in HL-60 and U937 cells, although normal induction of other IFN-regulated activities takes place. The latter group of cells shows a decline in c-myc gene expression when they become arrested in the G0/G1 phase as part of their terminal differentiation.